Ligand substitution reactions afford oxaliplatin-based platinum(<scp>iv</scp>) complexes bearing axial alkoxido ligands-Reference-Cited by-同舟云学术

Ligand substitution reactions afford oxaliplatin-based platinum(iv) complexes bearing axial alkoxido ligands

Published:2023 Issue:20 Volume:10 Page:6058-6066
ISSN:2052-1553
Container-title:Inorganic Chemistry Frontiers
language:en
Short-container-title:Inorg. Chem. Front.

Author:

Xu Zoufeng¹,Lin Long¹,Fu Binbin¹,Huang Fu-Ping²^ORCID,Zhou Qiyuan³,Zhu Guangyu³^ORCID,Wang Zhigang¹^ORCID

Affiliation:

1. School of Pharmacy, International Cancer Center, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong 518055, People's Republic of China

2. State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, Guangxi 541006, People's Republic of China

3. Department of Chemistry, City University of Hong Kong, 83 Tat Chee Ave, Kowloon Tong, Hong Kong SAR 999077, People's Republic of China

Abstract

Oxaliplatin-based platinum(iv) complexes bearing axial alkoxido ligands were obtained by substituting the trifluoroacetato ligand. These complexes exhibit enhanced stability and reduced cytotoxicity compared to their carboxylated platinum(iv) analogues.

Funder

Science and Technology Foundation of Shenzhen City

National Natural Science Foundation of China

State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources

Publisher

Royal Society of Chemistry (RSC)

Subject

Inorganic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/QI/D3QI01562A

Reference67 articles.

1. What blocks more anticancer platinum complexes from experiment to clinic: Major problems and potential strategies from drug design perspectives

2. The rediscovery of platinum-based cancer therapy

3. Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours

4. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial

5. Radiotherapy and Cisplatin Increase Immunotherapy Efficacy by Enabling Local and Systemic Intratumoral T-cell Activity